Quest Diagnostics Incorporated (DGX) Cash Flow Statement

The structural gap between operating cash flow and net income reflects a non-cash-heavy cost base where depreciation of $117M–$147M per quarter plus modest SBC consistently bridges reported earnings to cash generation. This pattern suggests relatively high earnings quality with limited accrual drag, though investors should recognize that working capital releases also inflate OCF in certain quarters without reflecting a step-change in underlying profitability.

The FCF trajectory exhibits pronounced seasonality, with Q1 consistently weakest due to deductible resets and weather-related volume softness, while Q3 delivers peak cash generation. The step-change to an 18.5% FCF margin in 2026Q3 appears to combine genuine operational momentum (raised guidance, 11.8% revenue growth) with a favorable working capital contribution; the durability of this margin warrants monitoring given the historical Q1-to-Q3 swing pattern.

The pattern of D&A outpacing CapEx in most quarters may suggest the existing asset base is being consumed faster than replaced, though the recent ramp from $92M in 2024Q2 to $166M in 2026Q3 could equally reflect growth investment in automation and specimen logistics capacity rather than deferred maintenance catch-up. For a logistics-intensive diagnostics operator, a CapEx/Rev ratio near 4–5% is structurally modest, meaning free cash flow generation is less exposed to capital replacement cycles than typical industrial peers.

The combination of a steadily growing baseline dividend and highly variable share repurchases suggests a capital allocation framework that prioritizes predictable returns while deploying surplus cash opportunistically. The $1.5B acquisition in 2024Q3 represents a material bet on inorganic growth, likely in hospital lab outsourcing; investors should evaluate whether the subsequent smaller tuck-in deals ($1M–$50M per quarter) are generating adequate returns relative to the cost of that initial outlay.

The consistent Q1 working capital outflows (2025Q1 at -$90M, 2026Q1 at -$210M) likely reflect a combination of tax settlement timing and insurance deductible resets that delay collections, with the larger 2026Q1 drain possibly indicating a heavier receivables build as revenue scaled. Given the fragmented multi-payer billing cycle inherent to this business, quarterly OCF figures should be smoothed across a full year before drawing conclusions about the underlying cash generation trend.